EU approves Otsuka's long-acting HAE drug Dawnzera
An EMA nod for Otsuka's Dawnzera offers EU patients with HAE a drug that can be self-administered by patients with up to eight weeks between doses.
Hopstem maps course to bring stem cell stroke therapy to US
China's Hopstem has been cleared to move straight to a phase 2 trial in the US for its stem cell-based therapy to aid recovery after a stroke.
ImmunityBio rises as route opens to broader Anktiva label
Shares in ImmunityBio shot up after it agreed a path with the FDA that should allow it to refile for wider use of its bladder cancer drug Anktiva.
Call goes out for type 1 diabetes screening in UK
A finger-prick screening programme for type 1 diabetes should roll out in the UK, say researchers, given a disease-modifying drug is now available.
Data builds behind Moderna's skin cancer vaccine
Five-year results with Moderna/MSD's melanoma jab show a 49% reduction in disease progression or death, boding well for phase 3 data later this year.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
Book your tickets and join the PM Society for the 40th PM Aw...
Tickets are on sale for the 40th anniversary of the PM Awards
The Pharmaceutical Manufacturing and Packaging Congress (PHA...
The Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2026 unites professionals to discuss the most recent trends of industry in Amsterdam
5th mRNA-Based Therapeutics Summit Europe
The Summit is the leading European industry-focused forum dedicated to accelerating the development of messenger RNA (mRNA) medicines
VuuAI and Amiculum partner to transform content engagement i...
Amiculum, a global health communications agency, has entered into an exciting strategic collaboration with VuuAI, a GenAI-driven content production automation plat
10th Tumor Models Summit San Francisco
Join the West Coast's premier pharma and biotech gathering, the 10th Tumor Models Summit San Francisco, where innovation meets opportunity